v3.25.1
Summary of significant transactions - Evolution of the total transaction price (Details) - EUR (€)
Dec. 31, 2024
Jan. 31, 2024
Dec. 31, 2023
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2015
Summary Of Significant Transaction [line items]                  
Purchase Commitment Related To Services From Novalix. € 41,600,000                
Gilead                  
Summary Of Significant Transaction [line items]                  
Upfront consideration 4,018,016,000   € 4,018,016,000   € 4,018,016,000        
Milestones achieved, balance 212,601,000   212,601,000   212,601,000        
Royalties, balance 50,780,000   40,176,000   30,710,000        
Impact initial valuation of share subscription 124,604,000   124,604,000   124,604,000        
Transaction price before warrants issuances liabilities 4,406,001,000   4,395,397,000   4,385,931,000        
Allocation to performance obligations 4,360,136,000   4,349,487,000   4,339,347,000        
Gilead | Other movements in 2023                  
Summary Of Significant Transaction [line items]                  
Royalties Amount Received     9,466,000            
Transaction price before warrants issuances liabilities     9,466,000            
Allocation to performance obligations     10,140,000            
Gilead | Other Movements In 2024 Member                  
Summary Of Significant Transaction [line items]                  
Royalties Amount Received 10,604,000                
Transaction price before warrants issuances liabilities 10,604,000                
Allocation to performance obligations 10,649,000                
Warrant A | Gilead                  
Summary Of Significant Transaction [line items]                  
Less : Warrants issuance liabilities (43,311,000)   (43,311,000)   (43,311,000)        
Initial Warrant B | Gilead                  
Summary Of Significant Transaction [line items]                  
Less : Warrants issuance liabilities (2,545,000)   (2,545,000)   (2,545,000)        
Subsequent warrant B | Gilead                  
Summary Of Significant Transaction [line items]                  
Less : Warrants issuance liabilities (9,000)   (54,000)   (728,000)        
Subsequent warrant B | Gilead | Other movements in 2023                  
Summary Of Significant Transaction [line items]                  
Less : Warrants issuance liabilities     674,000            
Subsequent warrant B | Gilead | Other Movements In 2024 Member                  
Summary Of Significant Transaction [line items]                  
Less : Warrants issuance liabilities 45,000                
Filgotinib Performance Obligation Member | Gilead                  
Summary Of Significant Transaction [line items]                  
Upfront consideration             € 160,000,000   € 275,600,000
Allocation to performance obligations 1,392,248,000   1,381,644,000   1,372,178,000        
Estimated significant financing component   € 39,300,000 39,800,000   58,700,000     € 44,500,000  
Filgotinib Performance Obligation Member | Gilead | Original Agreement                  
Summary Of Significant Transaction [line items]                  
Upfront consideration     4,000,000,000            
Filgotinib Performance Obligation Member | Gilead | First Revised Agreement                  
Summary Of Significant Transaction [line items]                  
Upfront consideration               € 3,600,000,000  
Filgotinib Performance Obligation Member | Gilead | Second Revised Agreement                  
Summary Of Significant Transaction [line items]                  
Upfront consideration             € 172,600,000    
Filgotinib Performance Obligation Member | Gilead | Amendments Relating To The Diversity Study [member]                  
Summary Of Significant Transaction [line items]                  
Upfront consideration           € 12,600,000      
Filgotinib Performance Obligation Member | Gilead | Other movements in 2023                  
Summary Of Significant Transaction [line items]                  
Allocation to performance obligations     9,466,000            
Filgotinib Performance Obligation Member | Gilead | Other Movements In 2024 Member                  
Summary Of Significant Transaction [line items]                  
Allocation to performance obligations 10,604,000                
Gilead collaboration agreement for ziritaxestat | Gilead                  
Summary Of Significant Transaction [line items]                  
Allocation to performance obligations 666,967,000   666,967,000   666,967,000        
Collaboration agreement for drug discovery platform | Gilead                  
Summary Of Significant Transaction [line items]                  
Allocation to performance obligations 2,300,921,000   2,300,876,000   € 2,300,203,000        
Collaboration agreement for drug discovery platform | Gilead | Other movements in 2023                  
Summary Of Significant Transaction [line items]                  
Allocation to performance obligations     € 674,000            
Collaboration agreement for drug discovery platform | Gilead | Other Movements In 2024 Member                  
Summary Of Significant Transaction [line items]                  
Allocation to performance obligations € 45,000                
Drug discovery collaboration transaction with NovAliX                  
Summary Of Significant Transaction [line items]                  
Collaboration Agreement Upfront Payment       € 8,300,000